SANTA MONICA, Calif., Dec. 30, 2014 (GLOBE NEWSWIRE) -- Kite Pharma, Inc., (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT™) products for the treatment of cancer, today announced that the underwriters of its previously announced follow-on public offering of 3,485,000 shares of common stock have exercised in full their option to purchase an additional 522,750 shares of common stock at the public offering price of $54 per share, less customary underwriting discounts and commissions. The closing of the option exercise is expected to occur on January 2, 2015.
Jefferies LLC, Credit Suisse Securities (USA) LLC and Cowen and Company, LLC acted as joint book-running managers for the offering. Stifel acted as co-manager.
Registration statements relating to these securities have been filed with the Securities and Exchange Commission and became effective on December 10, 2014. Copies of the final prospectus relating to the offering may be obtained from: Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, telephone: (877) 547-6340, e-mail: Prospectus_Department@Jefferies.com; Credit Suisse Securities (USA) LLC, Attention: Prospectus Department, One Madison Avenue, New York, NY 10010, telephone: (800) 221-1037, e-mail: newyork.prospectus@credit-suisse.com; or Cowen and Company, LLC, c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY, 11717, Attention: Prospectus Department, telephone: (631) 274-2806, fax: (631) 254-7140.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
CONTACT: Cynthia M. Butitta
Chief Financial Officer and Chief Operating Officer
(310) 824-9999
For Media: Justin Jackson
For Investor Inquiries: Nancy YuBurns McClellan
(212) 213-0006
jjackson@burnsmc.comnyu@burnsmc.com
Source: Kite Pharma, Inc.
News Provided by Acquire Media
